What will become of biotech in 2019? What’s the legacy of Sarepta Therapeutics? And how do you say “overhyped” in Mandarin?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Ike Swetlitz joins us to discuss the IBM’s latest travails with Watson Health, the purportedly revolutionary technology that has quickly become a cautionary tale. Then, we look forward to 2019 and the major biotech stories we’ll be keeping an eye on throughout the year. Finally, Dr. Ed Kaye, CEO of Stoke Therapeutics, joins us to talk about his new company, relive his days at Sarepta, and, bravely, answer rapid-fire questions in a lightning round.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy